Meet the OBR Editorial Board

Editor's Note: At OBR we have created an editorial board of renown thought leaders in different cancer disease areas. The role of our editorial board is to provide valuable insights through editorial commentary accompanying our daily news. We call it virtual access. By providing our insights into the daily news, you will have access into how these thought leading oncologists interpret the oncology news and events we carry in OBR daily. We hope that our editorial boards's insights will bring great value to the oncology community.

View all Editorial Board Member Commentary

Browse Editors by Section

member-photo

Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncology
The University of Texas MD Anderson Cancer Center

Comments

Scientists Identify Unique Genomic Features in Testicular Cancer

quotesThese findings are an example of the power of genomic sequencing and bioinformatic analysis - with a…quotes

member-photo

Howard S. Hochster, MD

Distinguished Professor of Medicine, Rutgers Robert Wood Johnson Medical School
Rutgers-CINJ Associate Director, Clinical Research
Director Clinical Oncology Research, RWJ-B Health System

Comments

Opdivo (nivolumab) in Combination with Yervoy (ipilimumab) Demonstrates Clinical Activity in Previously Treated Patients with dMMR or MSI-H Metastatic Colorectal Cancer

quotesGreat work by Mike Overman and colleagues showing prolonged benefit to Nivo (3 mg,kg) and Ipi (1 mg,…quotes

member-photo

Richard Goldberg, MD

Director WVU Cancer Institute
Director of Cancer Signature Program
Laurence S. and Jean J. DeLynn Chair of Oncology

Comments

Study Examines 'Watch-And-Wait' Approach for People with Rectal Cancer

quotesThis is a very interesting study that opens the door to prospective investigation of a randomized tr…quotes

member-photo

Ted Okon

Executive Director
Community Oncology Alliance

Comments

COA Files Lawsuit Against Federal Government to Stop Sequester Cut to Cancer Drug Reimbursement

quotesIt is very disappointing that this Administration would not undo the unconstitutional mistake of the…quotes

member-photo

William McGivney, PhD

National Health Policy Expert

Comments

Potential Administrative Burdens in Oncology Clinical Pathways

quotesCoincidently, I was lecturing last week at the Home of Guideline study, Dartmouth (at the Tuck Busin…quotes

member-photo

Tomasz M. Beer, MD, FACP

Professor of Medicine, Division of Hematology/Medical Oncology, School of Medicine
Grover C. Bagby Chair of Prostate Cancer Research
OHSU Knight Cancer Institute Deputy Director, OHSU Knight Cancer Institute, School of Medicine
Chief Medical Officer, CEDAR, OHSU Knight Cancer Institute, School of Medicine

No comments to show!

member-photo

H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Cancer Institute, Seattle, WA; CEO, Global Resource for Advancing Cancer Education (GRACE)

Comments

How An Old Diabetes Drug Made A Big Splash At The Biggest Cancer Confab

quotesThis work is certainly provocative, but there are several issues that should lead us to be cautious …quotes

member-photo

Winston Wong, PharmD

President, W-Squared Group

Comments

U.S. Medicare Sets Outpatient Rate For Yescarta Reimbursement

quotesCMS has set the reimbursement for their near normal outpatient rate, thus CMS is treating the CAR-T …quotes

member-photo

Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst

Comments

U.S. Food and Drug Administration Approves POMALYST® (pomalidomide) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma

quotesI am excited to be joining the editorial board on OBR; I have been a fan of the publication since it…quotes

member-photo

Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One

No comments to show!

member-photo

Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology
Department of Medicine,Cedars-Sinai Medical Center
Associate Director for Academic Program Development
Samuel Oschin Comprehensive Cancer Institute
Professor of Medicine and Urology, Emeritus
David Geffen School of Medicine at UCLA

Comments

CT Scans Can Reduce Lung Cancer Deaths, Study Finds

quotesThis long awaited trial performed by the National Cancer Institute demonstrates the benefits of low …quotes

member-photo

Dean Gesme, MD

FACP FACPE FASCO
President, Minnesota Oncology

Comments

FDA Commissioner Gottlieb: US Could See Lower Drug Prices If Europe Pays More Of Its Fair Share

quotesHow does this work? Higher prices in the non-US market are no assurance of lower prices in the US. …quotes

member-photo

Jeff Patton, M.D.

CEO
Tennessee Oncology

Comments

Oncologists Getting 6% of Drug Price Is 'Financial Conflict'

quotesThere are certainly some perverse incentives in medicine but there is a significant literature that …quotes

member-photo

Thomas Marsland, MD

Vice President
Integrated Community Oncology Network
Former Community Representative
ASCO Board of Directors

Comments

Opinions: There’s A Miraculous Chance To Cure Cancer. But We’ll Have To Pay For It.

quotesSo back to the grind stone... in clinic today after and exciting ASCO AM. But as this article su…quotes

member-photo

William Harwin MD

Florida Cancer Specialists
President and Managing Partner

Comments

Memorial Sloan Kettering to Offer DigniCap® Scalp Cooling Device in New York Metro Area Locations

quotesAt Florida Cancer Specialists we have been using DigniCap for several months at 3 of our site and it…quotes

member-photo

Howard Sandler, MD, MS, FASTRO

Ronald H. Bloom Chair in Cancer Therapeutics

Professor and Chair, Department of Radiation Oncology

Interim Director, Samuel Oschin Comprehensive Cancer Institute

Cedars-Sinai Medical Center

Comments

Radiotherapy Offers New Treatment Option for Liver Cancer

quotesInteresting experience using focal radiation techniques (with injected radiation) to treat HCC. Ther…quotes